What is Trellis Bioscience?
Trellis Bioscience operates at the intersection of biotechnology and advanced therapeutics, specializing in the discovery and development of human monoclonal antibodies (mAbs). At the core of its operations is the proprietary CellSpot platform, a technological framework that enables the rapid identification and development of high-affinity antibodies. The company's primary focus is addressing significant medical challenges, including prosthetic joint infections and various viral pathogens, as well as targeted cancer treatments. By leveraging its unique platform, Trellis Bioscience aims to improve patient outcomes and reduce the reliance on invasive medical procedures, positioning itself as a key player in the biopharmaceutical sector's effort to solve unmet clinical needs.
How much funding has Trellis Bioscience raised?
Trellis Bioscience has raised a total of $28.5M across 4 funding rounds:
Series A
$3.4M
Series B
$10M
Private Equity
$6.1M
Series C
$9M
Series A (2004): $3.4M, investors not publicly disclosed
Series B (2007): $10M, investors not publicly disclosed
Private Equity (2026): $6.1M, investors not publicly disclosed
Series C (2026): $9M featuring New Science Ventures, The AMR Action Fund, and Easton Capital
Key Investors in Trellis Bioscience
New Science Ventures
New Science Ventures is a venture capital firm that invests in early and late-stage companies utilizing novel scientific approaches to address significant unmet needs in the life sciences and information technology sectors.
The AMR Action Fund
The AMR Action Fund is a specialized investment vehicle dedicated to overcoming barriers in antibiotic development and ensuring a sustainable pipeline of treatments to combat antimicrobial-resistant infections.
Easton Capital
Easton Capital Investment Group manages institutional capital with a focus on strategic investments in growth-oriented companies, often leveraging co-investment relationships to support larger funding rounds.
What's next for Trellis Bioscience?
With the recent infusion of capital, Trellis Bioscience is poised to scale its clinical evaluation programs and further refine its therapeutic pipeline. The strategic focus will likely center on the advancement of TRL1068 and other lead candidates through rigorous regulatory milestones. As the company continues to build its intellectual property portfolio and clinical data, it will likely seek to strengthen its market position by fostering partnerships with healthcare providers and larger pharmaceutical entities. The focus remains on transforming innovative scientific research into scalable, life-saving treatments that address the growing global threat of antimicrobial resistance and complex oncological conditions.
See full Trellis Bioscience company page
